Atlas Trials

The Study Collect Clinical Data From the Treatment of Liver Cancer With New Drugs After 2019 and Integrate Biochemical and Pathological Indicators to Analyze Prognostic Outcomes, Including Overall Survival, Progression-free Survival, and Complications.

Clinical trial NCT07233759 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT07233759
Sponsor
National Taiwan University Hospital
Status
ACTIVE_NOT_RECRUITING
Study type
OBSERVATIONAL
Liver CancerPembrolizumabAtezolizumabLenvatinib
Start date
2023-01-31
Primary completion
2026-12-31
Enrollment
2500

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.